Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lori Grabois

Psychiatry Aventura, FL Medical Doctor

NPI 1952380933 CMS profile 315731

21110 Biscayne Blvd, Suite 304, Aventura, FL 33180

Open in the dashboard

General payments

$12,460

559 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lori Grabois of Aventura, FL is reported in the CMS Open Payments database as having received $12,460 across 559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,405 54
2024 General $1,714 72
2023 General $2,095 89
2022 General $2,600 108
2021 General $2,185 109
2020 General $1,221 64
2019 General $1,239 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lori Grabois
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lori Grabois were reported at $1,405. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lori Grabois Psychiatry median Middle half National median
2019 $1,239 $184 $59–$605 $163
2020 $1,221 $119 $36–$372 $114
2021 $2,185 $143 $43–$576 $132
2022 $2,600 $153 $50–$590 $149
2023 $2,095 $170 $56–$651 $160
2024 $1,714 $179 $57–$673 $164
2025 $1,405 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $2,005 84 payments
  2. Lundbeck LLC $1,377 67 payments
  3. Otsuka America Pharmaceutical, Inc. $1,291 65 payments
  4. Vanda Pharmaceuticals Inc. $957 42 payments
  5. Janssen Pharmaceuticals, Inc $930 29 payments
  6. AbbVie, Inc. $896 45 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $609 27 payments
  8. Teva Pharmaceuticals USA, Inc. $595 26 payments
  9. Allergan Inc. $573 37 payments
  10. Axsome Therapeutics, Inc. $565 16 payments
  11. Other $2,662 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,380 556 payments
  2. Education $80 3 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA Psychiatry $1,361 62 payments
  2. REXULTI Psychiatry $1,277 63 payments
  3. REXULTI Psychiatry $991 48 payments
  4. HETLIOZ $957 42 payments
  5. FANAPT $957 42 payments
  6. SPRAVATO $930 29 payments
  7. VRAYLAR Neuroscience $816 42 payments
  8. VRAYLAR Neuroscience $650 39 payments
  9. CAPLYTA Psychiatry $644 22 payments
  10. Auvelity $565 16 payments
  11. Other $6,181 293 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

839

Median for Psychiatry & Neurology: 100

Drug cost

$23,126

Median for Psychiatry & Neurology: $2,986

Branded share of claims

17.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 11 $15,409
Sertraline Hcl Generic 107 $767
Venlafaxine Hcl Er Venlafaxine Hcl Brand 63 $727
Bupropion Xl Bupropion Hcl Brand 34 $712
Lorazepam Generic 86 $683
Lamotrigine Generic 48 $630
Escitalopram Oxalate Generic 62 $490
Quetiapine Fumarate Generic 28 $444
Clonazepam Generic 90 $439
Mirtazapine Generic 37 $401

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$473 11 —
CAPLYTA
$352 — —
Auvelity
$224 — —
SPRAVATO
$143 — —
LOREEV XR
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record